Healthcare -
Biotechnology - NASDAQ - US
$ 1.77
-1.67 %
$ 116 M
Market Cap
-4.54
P/E
1. INTRINSIC VALUE
Balance Sheet
Zura Bio Limited
| Current Assets | 101 M |
| Cash & Short-Term Investments | 99.8 M |
| Receivables | 0 |
| Other Current Assets | 1.04 M |
| Non-Current Assets | 0 |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 0 |
| Current Liabilities | 20.3 M |
| Accounts Payable | 2.75 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 17.6 M |
| Non-Current Liabilities | 990 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 990 K |
EFFICIENCY
Earnings Waterfall
Zura Bio Limited
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 62.6 M |
| Operating Income | -62.6 M |
| Other Expenses | -2.08 M |
| Net Income | -60.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Zura Bio Limited
| Net Income | -60.6 M |
| Depreciation & Amortization | 168 K |
| Capital Expenditures | -8 M |
| Stock-Based Compensation | 9.66 M |
| Change in Working Capital | 5.12 M |
| Others | 29.9 M |
| Free Cash Flow | -23.1 M |
Wall Street Analysts Price Targets
Zura Bio Limited
Wall Street analysts predict an average 1-year price target for ZURA of $10 , with forecasts ranging from
a
low of
$5 to a high of $15 .
ZURA Lowest Price Target
Wall Street Target
5 USD
182.49%
ZURA Average Price Target
Wall Street Target
10 USD
464.97%
ZURA Highest Price Target
Wall Street Target
15 USD
747.46%
4. DIVIDEND
ANALYSIS
ZURA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Zura Bio Limited
Sold
0-3 MONTHS
2.73 M USD 1
3-6 MONTHS
10.5 M USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
4.75 M USD 5
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 month ago
Nov 25, 2024
|
Sell 2.73 M
USD
|
Thiara Parvinder
Director
|
- 1001633
|
2.73 USD |
|
4 months ago
Sep 11, 2024
|
Sell 10.3 M
USD
|
Thiara Parvinder
Director
|
- 3800000
|
2.7 USD |
|
4 months ago
Sep 04, 2024
|
Sell 200 K
USD
|
Sidhu Someit
Director
|
- 51728
|
3.87 USD |
|
8 months ago
May 17, 2024
|
Bought
496 K USD
|
Ploos van Amstel Arnout
Director
|
+ 80000
|
6.2 USD |
|
8 months ago
Apr 22, 2024
|
Bought
25 K USD
|
Howell Michael
See Remarks
|
+ 7987
|
3.13 USD |
|
8 months ago
Apr 22, 2024
|
Bought
10 K USD
|
Nistala Kiran
Executive Vice President
|
+ 3195
|
3.13 USD |
|
8 months ago
Apr 22, 2024
|
Bought
500 K USD
|
Munshi Amit
Director
|
+ 159744
|
3.13 USD |
|
8 months ago
Apr 22, 2024
|
Bought
3.72 M USD
|
Sidhu Someit
Director
|
+ 1186901
|
3.13 USD |
7. News
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in adults.
businesswire.com
- 3 weeks ago
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY. A live webcast and a replay of the presen.
businesswire.com
- 1 month ago
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17A.
businesswire.com
- 2 months ago
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 trial of tibulizumab in SSc. We've worked closely with our contract research organization (CRO) to.
businesswire.com
- 2 months ago
Zura Bio to Participate in Two Upcoming Investor Conferences in November
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in two investor conferences in November. Conference Details: Event: Guggenheim Inaugural Healthcare Innovation Conference Details: Participating in a fireside chat on Tuesday, November 12, 2024, at 1:00 p.m. ET.
businesswire.com
- 2 months ago
CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology
SACRAMENTO, Calif.--(BUSINESS WIRE)--CPS HR Consulting, a leader in public sector HR consulting, is thrilled to announce a strategic partnership with GovInvest, the pioneer of compensation analytics technology for government agencies. This collaboration aims to combine CPS HR's renowned compensation consulting expertise with GovInvest's innovative software platform, offering unparalleled data confidence and decision-making capabilities. Highlights of the Partnership Best-in-Class Consulting + T.
businesswire.com
- 4 months ago
3 Undervalued Biotech Stocks With Breakout Potential
Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies.
investorplace.com
- 6 months ago
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow.
investorplace.com
- 6 months ago
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren's syndrome. These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Co.
businesswire.com
- 7 months ago
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Forms Scientific Advisory Board with Prominent Specialists.
businesswire.com
- 7 months ago
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data from its tibulizumab (ZB-106) program exploring the clinical potential of the dual-pathway antibody in Sjogren's syndrome and rheumatoid arthritis (RA) at EULAR 2024, June 12-15 in Vienna. “We are excited to present translational data from our tibulizumab (ZB-106.
businesswire.com
- 7 months ago
Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know
The consensus price target hints at a 235.2% upside potential for Zura Bio Limited (ZURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
- 7 months ago
8. Profile
Summary
Zura Bio Limited ZURA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 116 M
Dividend Yield
0.00%
Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Contact
4225 Executive Square, San Diego, CA, 92037
https://zurabio.com
IPO
Date
March 21, 2023
Employees
14
Officers
Ms. Kimberly Ann Davis
Chief Legal Officer & Corporate Secretary
Ms. Theresa Lowry
Chief Human Resources Officer
Mr. David Brady
Head of Business Development
Dr. Kiran Nistala MBBS, Ph.D.
Chief Medical Officer & Head of Development
Mr. Verender S. Badial
Chief Financial Officer
Mr. Robert Lisicki
Chief Executive Officer & Director
Dr. Gary Whale Ph.D.
Chief Technology Officer
Dr. Someit Sidhu M.D.
Founder & Director